Targeting protein SAP2 restores mosquito sensitivity to pyrethroid insecticides
Release date: 2020-01-07 Views: 0
In a new study, researchers from the Liverpool School of Tropical Medicine in the UK have discovered a whole new mechanism for insecticide resistance in mosquitoes carrying the Plasmodium parasite. After studying two major malaria vectors in West Africa-Anopheles gambiae and Anopheles coluzzii-they found that a specific family of binding proteins located on the mosquito legs was Insecticide-resistant mosquito populations are highly expressed. The relevant research results were recently published in the journal Nature and the title of the paper was "A sensory appendage protein protects malaria vectors from pyrethroids".
The first author of the paper, Dr. Victoria Ingham explained, "We have discovered a new mechanism of insecticide resistance, which we believe is causing the mosquito net to be less effective than expected. When mosquitoes stay on the mosquito net, the mosquito The direct binding of the binding protein on the leg to the insecticide makes it an excellent potential target for future development of additives to be added to mosquito nets to overcome this powerful resistance mechanism. "
After studying the two Anopheles species, the researchers found that the binding protein SAP2 was elevated in the insecticide-resistant mosquito population and was a type of insecticide used on all nets-pyrethroids (pyrethroids) ) --- It will rise further after exposure. They found that mosquitoes' sensitivity to pyrethroids could be restored when their expression levels were reduced by partially silencing the gene encoding the protein. Conversely, when this protein is expressed at high levels, mosquitoes that were previously sensitive to pyrethroids become resistant to such insecticides.
The increased insecticide resistance of the entire mosquito population has led to the introduction of new insecticide-treated mosquito nets containing the synergist piperonyl butoxide (PBO) and pyrethroid insecticides. This synergist targets one of the most extensive and previously most effective drug resistance mechanisms caused by cytochrome P450. However, mosquitoes are constantly developing new resistance mechanisms. The discovery of this new drug resistance mechanism provides an excellent opportunity to identify other synergists that can be used to restore susceptibility.
Crucially, the research has enabled humans to better understand and reduce insecticide resistance in mosquito populations to ensure that the sharp decline in disease incidence over the past decades is irreversible. This newly discovered drug resistance mechanism may provide important targets for us to monitor insecticide resistance, develop novel compounds that can block pyrethroid resistance and prevent malaria transmission. "
- Basic introduction of Heilongjiang Hexiang Pharmaceutical Co., Ltd.
- How to contact Bermuda Medical (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Brief introduction of Zaozhuang Yinhai Pharmaceutical Co., Ltd.
- Contact information of Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Introduction of Bermoudi (Shanghai) Regenerative Medicine Technology Co., Ltd.
- 开始了！ 1. It's started! 6 illegal actions at designated drug stores
- 有望中美申报上市！ 2. China and the United States are expected to apply for listing! Yifan Pharmaceutical's Class 1 new drug F-627 Phase III clinical success in China
- 『医药头条君』新药研发如何越来越好？ 3. How is the research and development of new drugs in "Medical Headlines" getting better and better? 2019 CDE chemical drug review report
- 2019年全球十大热门生物技术盘点 4. Inventory of the world's top ten hot biotech in 2019
- 重磅！ 5. Heavy! Domestic application for the fourth indication of O drug
- 2019 CDE年度药审报告：589个化药1类申请1045个ANDA 6. 2019 CDE annual drug review report: 589 chemical drugs, Class 1 applications, 1045 ANDA
- 达格列净上市申请获FDA优先审查 7. Dagle's net listing application receives FDA priority review